Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07541677

Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity

Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%.

In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups.

The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments.

Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • body mass index ≥ 27.5kg/m2
  • able to provide informed consent.

Exclusion criteria

  • unable to undergo the physical function tests (handgrip strength testing and chair-stand tests)
  • pregnant women
  • history of bariatric procedures or surgeries
  • on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)

Treatment and study plan

Primary outcomes

  1. Sarcopenia

    Time frame: Outcome measures will be recorded at baseline only.

    Skeletal muscle mass Skeletal muscle mass measurement will be obtained via bioimpedance analysis using the TANITA MC 780 MA Multi-frequency Segmental Body Composition Analyser. Low skeletal muscle mass will be defined by percentage of skeletal muscle mass divided by body weight of ≤ 37% in males and ≤ 27.6% in females.

  2. Handgrip strength

    Time frame: Outcome measures will be recorded at baseline only.

    Handgrip strength will be measured using the Jamar handgrip dynamometer. Two trials will be performed for each hand, and the maximum strength will be used for diagnosis.

  3. 5-time chair stand test

    Time frame: Outcome measures will be recorded at baseline only.

    Time taken (seconds) to perform 5 sit-to-stand repetitions

  4. 30-second sit-to-stand test

    Time frame: Outcome measures will be recorded at baseline only.

    Number of sit-to-stand repetitions performed in 30 seconds

Secondary outcomes

  1. Aerobic capacity

    Time frame: At baseline

    The study will use a validated non-exercise prediction model comprising a physical activity questionnaire to estimate peak oxygen uptake, VO2 milliliter/kg/minute (ml/kg/min). This simple physical activity questionnaire consists of age, gender, height, weight, estimated maximum heart rate, frequency of exercise, length of time for each workout, intensity of each workout, waistline diameter, and resting heart rate. It will be self-administered or administered with the assistance of the clinical research coordinator if required.

  2. Physical activity questionnaire

    Time frame: At baseline

    Number of minutes per week spent on moderate to vigorous physical activity will be recorded

  3. Dietary questionnaire

    Time frame: At baseline

    72 hour dietary recall questionnaire will be administered and dietary macronutrient composition will be calculated

Sponsors and collaborators

Lead sponsor

Singapore General Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Apr 21, 2026
Registry last updated
Apr 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.